CJC-1295 With DAC vs No DAC (Mod GRF 1-29): The Real Difference

If you have shopped grey-market peptide vendors, you have seen "CJC-1295 with DAC" and "CJC-1295 no-DAC" (often labeled "Mod GRF 1-29" or "modified GRF 1-29") sold side by side as if they were two strengths of the same drug. They are not. They are two different molecules with very different durations of action, and the choice between them is the single most consequential decision in how people use this peptide. This is an honest look at what "DAC" actually changes, what the limited human data show, and where the marketing outruns the evidence.

The honest headline, stated first: the DAC vs no-DAC distinction is real and well-characterized at the level of pharmacokinetics — DAC produces a multi-day elevation of GH and IGF-1, no-DAC produces a brief pulse — but there is no trial showing that either version improves muscle, fat loss, recovery, or athletic performance in healthy people. Both are unapproved research chemicals, used off-label, banned in tested sport under WADA category S2, and sold through a grey market where you cannot verify what is in the vial. Keep that frame for every mechanism below.

What "DAC" Actually Means

DAC stands for Drug Affinity Complex — a chemical modification, not a dose. The base peptide in both products is a modified fragment of growth-hormone-releasing hormone (GHRH): the first 29 amino acids of GHRH, with a few amino-acid substitutions that make it more stable than the natural hormone. That short, stabilized fragment, on its own, is what vendors sell as "CJC-1295 no-DAC" or Mod GRF 1-29.

"CJC-1295 with DAC" is that same fragment with an extra chemical group bolted on — a maleimidoproprionic acid linker that lets the peptide bind covalently to albumin, the most abundant protein in your blood, shortly after injection. Once it is riding on albumin, the peptide is shielded from the enzymes that would normally chew it up within minutes. The result is a peptide that circulates for days instead of minutes. This albumin-binding "drug affinity complex" design is the entire point of the DAC version, and it is exactly the modification that anti-doping laboratories built mass-spectrometry assays to detect⁶.

So the two products differ by one structural feature with one enormous functional consequence: half-life.

The Pharmacokinetic Difference — Stated From the Data

This is where the only real human evidence lives, and it is worth being precise about what it does and does not cover.

The DAC version has exactly one published human pharmacokinetic study — Teichman and colleagues, 2006, in healthy adults. A single subcutaneous injection of CJC-1295 (with DAC) raised growth hormone for up to about six days and IGF-1 for up to roughly nine to eleven days, with a measured half-life on the order of several days¹. That is a genuine, peer-reviewed finding, and it confirms the core claim: the DAC modification turns a peptide that would last minutes into one that "bleeds" GH and IGF-1 release across most of a week from one shot. The same study is why DAC is dosed roughly weekly rather than daily.

The no-DAC version (Mod GRF 1-29) has no comparable dedicated human PK study at all. Its short-acting behavior is inferred from the parent molecule: native and 1-29 GHRH peptides are cleared from the bloodstream within minutes, producing a sharp, brief GH pulse rather than a sustained elevation. The closest controlled human evidence for the short-acting GHRH(1-29) approach is older work giving GHRH 1-29 as single nightly injections to healthy elderly men, which raised GH and IGF-1 — a real but short, small, marker-based study, not an outcome trial³. The principle that you can engineer a GHRH analog to last far longer is also well documented: a separate long-acting (PEGylated) GHRH analog was shown to sustain GH release in healthy young and elderly subjects⁹, the same general strategy DAC uses with albumin instead of PEG.

So the data picture is lopsided: one small human PK study for DAC, essentially none specific to no-DAC, and zero outcome trials for either.

Why People Choose One Over the Other

The duration difference drives two genuinely different usage philosophies — and it is worth stating the rationale fairly before noting the catch.

No-DAC (Mod GRF 1-29) is favored by people who want to mimic the body's natural GH rhythm. GH is normally released in pulses; a short-acting GHRH peptide produces a brief spike and then lets levels fall, preserving that pulsatility. This is why no-DAC is almost always stacked with a ghrelin-mimetic GHRP such as ipamorelin — the two hit different receptors and produce a larger, sharper combined pulse. That logic is the basis of the popular ipamorelin + CJC-1295 stack, which in practice almost always means the no-DAC/Mod GRF 1-29 version, dosed several times a day around sleep and training.

DAC is favored by people who want convenience and a steady elevation: one or two injections a week instead of two or three a day. The trade-off is that DAC produces a continuous "bleed" of GH rather than discrete pulses — and a continuous, non-pulsatile GH signal is arguably less physiologic than the body's natural rhythm. Whether that matters for any real outcome is unknown, because, again, no outcome trial exists for either version.

For the broader physiology of how these GHRH and ghrelin peptides relate to recovery, see our pillar on GH peptides and recovery.

The Outcome Gap — The Part the Marketing Skips

Here is the honest core of the whole comparison. Neither CJC-1295 with DAC nor no-DAC has ever been shown, in a randomized controlled trial, to improve body composition, strength, recovery, or athletic performance in healthy people. The only human data on the DAC version measured hormones in the blood, not anything you would feel, see, or perform¹. Raising GH and IGF-1 is a surrogate marker — and the GH-secretagogue field has a long, sobering record of the marker rising while the outcome does not.

The most informative cautionary data come from MK-677 (ibutamoren), a far better-studied GH secretagogue. In a randomized, placebo-controlled trial in healthy older adults, it reliably raised GH and IGF-1 and increased fat-free mass — but did not improve strength or function⁴. Growth-hormone secretagogues as a class reliably raise serum IGF-1 in humans⁵; that is not in doubt. What is missing — for CJC-1295 specifically, in either form — is a single trial showing the biomarker bump becomes the muscle, leanness, or recovery that people buy it for. A recent structured review of injectable peptides in sports medicine reaches the same verdict: the human outcome evidence for GHRH-analog peptides like CJC-1295 is absent, and use is dominated by anti-doping and safety concerns rather than proven benefit¹⁰.

This is the same evidence trap that defines the category. Our evidence-first pillar on peptides for athletic recovery and our review of GH peptides and recovery walk through the identical pattern: a plausible mechanism, real biomarker movement, and a missing human outcome trial.

"Before and After": What's Actually Being Seen

Search either product with "before and after" and you will find transformation photos. Be precise about what they show. A peptide that raises GH — and especially one that, like the DAC version, sustains it for days — can drive fluid retention and a fuller, sometimes puffier look, plus the subjective sense of better sleep. None of that is evidence of the lean-mass-and-fat-loss recomposition the photos imply, and anecdotes cannot separate the peptide from training, diet, water retention, lighting, or placebo. A testimonial is not data — and for these peptides, the controlled data do not exist.

The Anti-Doping and Legal Reality

For any drug-tested athlete, the DAC-vs-no-DAC debate is moot: both end a career. GHRH analogs fall under the World Anti-Doping Agency Prohibited List category S2 (peptide hormones, growth factors, related substances and mimetics), banned at all times, in and out of competition. Anti-doping science treats them as a priority target — laboratories have developed mass-spectrometry methods specifically to detect GHRH analogs like CJC-1295⁶ and to screen for low-molecular-weight peptide drugs in athlete samples⁷. The U.S. Anti-Doping Agency lists peptide hormones and growth factors of this kind as prohibited and warns athletes directly against "research chemical" peptides⁸. We cover the full compliance picture in our guide to whether GH peptides are safe and legal.

The Grey-Market Quality Problem

Neither version is an FDA-approved drug. The FDA has moved peptides of this kind off the list of substances pharmacies may freely compound for human use, citing limited safety data and the difficulty of controlling peptide purity¹¹. The practical result: nearly all CJC-1295 — DAC or not — is sold "for research use only" by grey-market vendors. That adds a risk independent of the peptide itself: you cannot verify what is in the vial, whether the "DAC" version even carries the albumin-binding modification it claims, or whether the dose on the label matches the contents. Independent testing of research-chemical peptides has repeatedly found identity, purity, and dosing inconsistencies, and unapproved injectables add contamination and sterility risk on top of that.

Bottom Line

The DAC-vs-no-DAC distinction is real, and it is the most important thing to understand about CJC-1295: DAC binds albumin to produce a multi-day "bleed" of GH and IGF-1 from a weekly shot, while no-DAC (Mod GRF 1-29) is a short-acting fragment that makes a brief pulse, usually stacked with a GHRP like ipamorelin and dosed daily. That much is backed by the one human PK study on the DAC version and by the known clearance of short GHRH fragments. What neither version has is the thing that actually matters: a single human trial showing it improves body composition, strength, recovery, or performance. Layered on top of that evidence gap are three hard facts — both are unapproved research chemicals, both are WADA-banned in tested sport, and the grey-market supply is unreliable. For where these peptides sit against the rest of the category — and which providers offer them with real oversight versus none — see our evidence-ranked guide to the best recovery peptides. And for the sermorelin-vs-CJC-1295 angle on the GHRH side, our partner site somnipeptide covers [sermorelin vs CJC-1295](https://somnipeptide.com/sermorelin-vs-cjc-1295).